Biovista enters into agreement with Novartis
Biovista is a biotechnology company that profiles novel uses and side effects for existing drugs using their mechanism of action. Biovista president Aris Persidis said they look forward
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).